Cefotiam is a broad-spectrum cephalosporin antibiotic.1 It inhibits the growth of the Gram-positive bacterium S. aureus (MIC50 = 0.26 µg/ml) and the Gram-negative bacteria P. aeruginosa, E. coli, and H. influenzae (MIC50s = 1, 0.06, and 0.01 µg/ml, respectively). Cefotiam increases survival in mouse models of infection with the 853E and 630E strains of S. aureus (ED50s = 3.5 and 8.3 mg/kg, respectively) and various strains of E. coli (ED50s = 0.5-25 mg/kg).2 Formulations containing cefotiam have previously been used in the treatment of bacterial infections.
1.Limbert, M., Klesel, N., Seeger, K., et al.Cefodizime, an aminothiazolylcephalosporin. I. In vitro activityJ. Antibiot. (Tokyo)37(8)892-900(1984) 2.Acred, P., Ryan, D.M., Sowa, M.A., et al.The in-vivo antibacterial activity of ceftazidime (Gr 20263)--a comparison with other new β-lactam antibiotics and gentamicinJ. Antimicrob. Chemother.8 Suppl. B247-255(1981)